ASX:CUV Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Clinuvel Pharmaceuticals Stock (ASX:CUV) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Get CUV alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume124,193 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield0.36%Price TargetN/AConsensus RatingN/A Company OverviewClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.Read More… The Crypto That’s Making Wall Street Sweat (Ad)The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Receive CUV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CUV Stock News HeadlinesMA Financial Group Sticks to Its Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)October 30, 2024 | markets.businessinsider.comHealth Check: 4D Medical investors – and burns pit victims – can breathe easier after US lung-imaging dealOctober 1, 2024 | msn.comThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.November 12, 2024 | Crypto 101 Media (Ad)Top Growth Companies With Significant Insider OwnershipSeptember 28, 2024 | finance.yahoo.comSeptember 2024's Top Growth Picks With High Insider OwnershipSeptember 20, 2024 | finance.yahoo.comClinuvel Pharmaceuticals (ASX:CUV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSeptember 11, 2024 | finance.yahoo.com3 High Growth ASX Companies With Significant Insider OwnershipSeptember 8, 2024 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Impedimed Limited (IPDQF), Clinuvel Pharmaceuticals Limited (CLVLF)September 4, 2024 | markets.businessinsider.comSee More Headlines CUV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN). Company Calendar Ex-Dividend for 9/19 Dividend9/04/2024Dividend Payable9/19/2024Today11/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CUV CUSIPN/A CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.70 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$35.64 million Net Margins40.41% Pretax MarginN/A Return on Equity19.39% Return on Assets14.29% Debt Debt-to-Equity Ratio0.43 Current Ratio8.81 Quick Ratio10.03 Sales & Book Value Annual Sales$88.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow19.36 Book ValueA$4.05 per share Price / BookN/AMiscellaneous Outstanding Shares50,060,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.92 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (ASX:CUV) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersAI's Growing Energy Demands: The Urgent Need for Nuclear PowerAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWhy Trump’s Win Can’t Stop the Coming Crisis - Protect Yourself NowNo matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBreaking News: Are Trump/Musk Planning an AI Takeover? (Shocking)Now that he is Donald Trump’s right-hand man… You owe it to yourself to see Elon Musk’s big AI prediction f...Traders Agency | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
